Global Cell Based Assay & High Content Screening Market Research Report 2023: Focus on Key Developments Such as 3D Assays, Automation, Software, Primary Cells, & Signaling and Reporter Genes
DUBLIN, Jan. 18, 2023 /PRNewswire/ -- The "Cell Based Assay & High Content Screening Markets. Forecasts by User and Product. With Executive and Consultant Guides. including Customized Forecasting and Analysis. 2022 to 2026" report has been added to ResearchAndMarkets.com's offering.
Cell Based Assays are a mainstay of drug development and scientific research, and now, post pandemic, research activity is taking off. On top of this new technology is allowing Cell Based Assays to be used to measure any aspect of cell function.
This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity. The technology is moving faster than the market.
Genomics and Immunology are playing a role too. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
Key Topics Covered:
4.1.5 Cell Line and Reagent Supplier
4.1.6 Pharmaceutical Company
4.1.7 Audit Body
4.1.8 Certification Body
5. Market Trends
5.1 Factors Driving Growth
5.1.1 Candidate Growth
5.1.3 Genomic Blizzard
5.1.4 Technology Convergence
5.1.5 The Insurance Effect
5.2 Factors Limiting Growth
5.2.1 CBA Development Challenges
5.2.2 Instrument Integration
5.3 Technology Development
5.3.1 3D Assays
5.3.4 Primary Cells
5.3.5 Signaling and Reporter Genes
5.3.6 The Next Five Years
6. Cell Based Assays Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Nanolive closes a USD 20 million Funding Round
6.3 Depixus Seeks to Commercialize 'Magnetic Tweezers' for Drug Discovery
6.4 BioAuxilium Research Expands its Cell Signaling Assay Portfolio
6.5 Droplet Genomics Debuts New Microfluidic Screening Platform
6.6 DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide
6.7 Secondcell Bio to Make Creation of Cell Lines Easy
6.8 Nanolitre-scale cell assays developed with droplet microarray mass spec
6.9 Thermo Fisher Scientific Acquires Cell Sorting Technology
6.10 Cellink to Distribute Phasefocus High-Content Cell Imaging Platform
6.11 Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
6.12 Cancer Genetics to Acquire Organoid Startup Stemonix
6.13 Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
6.14 CRISPR Screens Uncover Novel Cancer Therapy Targets
6.15 ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam
6.16 New Transcriptomics Assay Facilitates Compound Screens
6.17 Carta Biosciences Betting on Gene Interaction Mapping
6.18 High-throughput Identifies cancer drug candidates
6.19 Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity
6.20 InSphero platform selected to test Cyclerion's sGC stimulator technology
6.21 OcellO to provide in vitro research services to Merus
6.22 Charles River Laboratories to acquire Citoxlab
6.23 Reaction Biology Corporation Purchases ProQinase GmbH
7. Profiles of Key Cell Based Assay Companies
7.3 Aurora Instruments Ltd.
7.5 Beckman Coulter Diagnostics
7.6 Becton, Dickinson and Company
7.8 Bio-Rad Laboratories, Inc.
7.9 BioTek Instruments
7.10 BioVision, Inc.
7.11 BMG Labtech
7.12 Cell Biolabs, Inc.
7.13 Cell Signaling Technology, Inc.
7.14 Charles River Laboratories
7.15 Cisbio Bioassays
7.16 Corning, Inc.
7.18 Enzo Life Sciences, Inc.
7.19 Eurofins DiscoverX Corporation
7.20 Evotec AG
7.21 Excellerate Bioscience
7.22 Fujifilm Cellular Dynamics International
7.25 Horizon Discovery
7.27 Leica Biosystems
7.28 Lonza Group Ltd.
7.29 Luminex Corp
7.30 Merck & Co., Inc
7.31 Miltenyi Biotec
7.32 Molecular Devices
7.35 New England Biolabs, Inc.
7.37 Origene Technologies
7.38 Perkin Elmer
7.40 Qiagen Gmbh
7.41 Reaction Biology
7.42 Recursion Pharma
7.43 Roche Diagnostics
7.47 Sony Biotechnology
7.48 SPT Labtech
7.49 Stemcells Technologies Canada Inc.
7.51 Thermo Fisher Scientific Inc.
7.52 Vitro Biopharma
8. Global Market Size
8.1 Global Market Overview by Country
8.2 Global Market by User - Overview
8.3 Global Market by Product Class - Overview
9. Global Market by User Type
10. Cell Based Assay by Product Class
11.1 FDA Cancer Drug Approvals by Year
11.2 Clinical Trials Started 2010 to 2016
11.3 Share of Pharma R&D by Country
For more information about this report visit https://www.researchandmarkets.com/r/nrlsez
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View original content:https://www.prnewswire.com/news-releases/global-cell-based-assay--high-content-screening-market-research-report-2023-focus-on-key-developments-such-as-3d-assays-automation-software-primary-cells--signaling-and-reporter-genes-301724318.html
SOURCE Research and Markets